Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-28
2011-12-20
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S285000
Reexamination Certificate
active
08080557
ABSTRACT:
The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I)wherein R1, L1, L2, X, Y and Z have defined meanings.
REFERENCES:
patent: 3274194 (1966-09-01), Hayao
patent: 3919425 (1975-11-01), Vidrio et al.
patent: 0013612 (1983-11-01), None
patent: 391462 (1990-10-01), None
patent: 2436781 (1980-04-01), None
patent: 1991/012006 (1991-08-01), None
patent: WO 9322309 (1993-11-01), None
patent: 1999/029687 (1999-06-01), None
patent: 2002/048117 (2002-06-01), None
Takai et al. Chemical and Pharmaceutical Bulletin, 1986, 34(5), 1907-16.
Herndon et al. Journal of Medicinal Chemistry, 1992, 35(26), 4903-10.
Kornet et al. (Journal of Heterocyclic Chemistry, 1984, 21(5), 1533-35.
Hazard et al. Therapie, 1965, 20(4), 1043-9.
Calabrese et al. Journal of the National Cancer Institute, 2004, 96(1), 56-69.
Tentori et al. Pharmacological Research, 2005, 52, 25-33.
“Cancer definition”, http://www.medterms.com/script/main/art.asp?articlekey=2580, accessed Nov. 27, 2007.
“Prostate Cancer Prevention”, http://www.cancer.gov/cancertopics/pdq/prevention/prostate/Patient, accessed Apr. 9, 2010.
Takai, H., et al: “Synthesis of piperidine derivatives with a quinazoline ring system as potential antihypertensive agents”, Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, vol. 34, No. 5, 1986, pp. 1907-1916, XP002333132, ISSN: 0009-2363, example 2a.
Hayao, S., et al:“New sedative and hypotensive 3-substituted 2,4(1H,3H)- quinazolidinediones” Journal of Medicinal Chemistry, vol. 8, 1965, pp. 807-811, XP002347459, the whole document.
Herndon, J.L. et al: “Ketanserin Analogues: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding” Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 35, 1992, pp. 4903-4910, XP000941731, ISSN: 0022-2623, table II; compounds 1,8-11,17.
Database WPI 'Online! Derwent Publications Ltd., London, GB; XP002347462, retrieved from WPI accession No. 1970-18449R, *see RN 27634-66-9: 3-(piperidin-1-yl-propyl)-1H-quinazoline-2,4-dione*, abstract & JP 45007058B (Sankyo) Jul. 6, 1967.
Costantino, G., et al: J. Med. Chem., vol. 44, No. 23, 2001, pp. 3786-3794, XP002347460, p. 3788.
International Search Report and Written Opinion, PCT/EP2005/053031, dated Oct. 25, 2005, 12 pages.
Kennis Ludo Edmond Josephine
Mertens Josephus Carolus
Somers Maria Victorina Francisca
Van Dun Jacbous Alphonsus Josephus
Wouters Walter Boudewijn Leopold
Janssen Pharmaceutica NV
Jarrell Noble
LandOfFree
Quinazolinedione derivatives as PARP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolinedione derivatives as PARP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolinedione derivatives as PARP inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312961